Presentation (CTI)

OBJECTIVES: This study aimed to address this gap by conducting a comprehensive evaluation of the effects of the system on stakeholders who are directly involved in Drug Track and Trace (RSD) implementation and operations within the Saudi healthcare system. We assessed the effect of RSD implementation on various stakeholder groups. This includes evaluating the experiences of stakeholders with fully integrated systems, those in the process of integration, and those yet to initiate the process and Identifying key factors influencing the effectiveness of RSD implementation, which involves identifying factors that enhance efficiency and those that create challenges in the implementation process, with the aim of optimizing implementation strategies and addressing challenges effectively.
METHODS: A cross-sectional, quantitative study was conducted using a structured survey. Participants were categorized into three groups: those who fully implemented RSD, those in the process of implementation, and those yet to initiate. The survey assessed system utility, challenges, and overall experiences. Data analysis involved the application of descriptive statistics to summarize the responses through frequency distributions and percentages.
RESULTS: Survey responses were received from 129 of 341 stakeholders. Of the 100 (77.5%) organizations that had fully implemented the RSD system, significant improvements were observed in key operational areas. Notably, 50% reported enhancements in drug traceability, 42% indicated improved product safety, and an 80% increase in operational efficiency. Organizations currently undergoing implementation cited technical difficulties (65%), high integration costs (40%), and resistance to change (10%) as the primary challenges. Conversely, those yet to embark on implementation mentioned a lack of technical expertise (78%) and financial constraints (11%) as significant barriers.
CONCLUSIONS: The RSD system shows promise for optimizing Saudi Arabia's pharmaceutical supply chain by enhancing inventory management, traceability, and product safety. However, technical and financial challenges must be addressed to realize its full potential and ensure a robust, secure pharmaceutical supply chain.